文献速递肿瘤 PET/CT

[68Ga]Ga-NYM046 PET/CT与18F-FDG PET/CT诊断透明细胞肾细胞癌的价值比较

Value of [68Ga]Ga-NYM046 PET/CT, in Comparison with 18F-FDG PET/CT, for Diagnosis of Clear Cell Renal Cell Carcinoma.
PubMed 文献 · J Nucl Med · 2024-12-03

本研究在OS-RC-2荷瘤小鼠中评估[68Ga]Ga-NYM046的体内分布,并纳入12例透明细胞肾细胞癌患者完成配对[68Ga]Ga-NYM046与18F-FDG PET/CT检查。结果显示[68Ga]Ga-NYM046 PET/CT检出的原发肿瘤、受累淋巴结和远处转移均多于18F-FDG PET/CT。原发肿瘤SUVmax在[68Ga]Ga-NYM046 PET/CT中显著更高,受累淋巴结SUVmax在18F-FDG PET/CT中更高,远处转移两者无显著差异。

要点

  • 12例透明细胞肾细胞癌患者中,[68Ga]Ga-NYM046 PET/CT检出原发肿瘤9个、受累淋巴结95个、远处转移137个,均多于18F-FDG PET/CT。
  • 原发肿瘤SUVmax中位数[68Ga]Ga-NYM046为13.5,18F-FDG为2.4,前者显著更高(P=0.008)。
  • 受累淋巴结SUVmax中位数18F-FDG为7.6,[68Ga]Ga-NYM046为5.9,后者显著更低(P=0.001)。

核心结论

  • [68Ga]Ga-NYM046 PET/CT为检测透明细胞肾细胞癌患者的原发肿瘤、受累淋巴结和远处转移提供了一种可行的策略。

研究设计与样本

  • 在OS-RC-2荷瘤小鼠中评估[68Ga]Ga-NYM046的体内生物分布。
  • 纳入12例透明细胞肾细胞癌患者,全部完成配对的[68Ga]Ga-NYM046 PET/CT与18F-FDG PET/CT检查。
  • 比较两种PET示踪剂的诊断效能,并将病理组织切片碳酸酐酶IX阳性率与PET/CT所得SUVmax进行比较。

主要发现

  • 注射后1小时,[68Ga]Ga-NYM046在OS-RC-2荷瘤模型的肿瘤摄取为7.21 ± 2.39 每克组织注射剂量百分比。
  • 除肿瘤外,肾脏和胃显示高摄取分布。
  • 12例患者中共评估9个原发肿瘤、96个受累淋巴结和147个远处转移。
  • 与18F-FDG PET/CT相比,[68Ga]Ga-NYM046 PET/CT检出更多原发肿瘤(9 vs. 1)、受累淋巴结(95 vs. 92)和远处转移(137 vs. 127)。
  • 原发肿瘤SUVmax中位数[68Ga]Ga-NYM046为13.5 vs. 18F-FDG为2.4(z=-2.668,P=0.008),前者显著更高;受累淋巴结SUVmax中位数[68Ga]Ga-NYM046为5.9 vs. 18F-FDG为7.6(z=-3.236,P=0.001),后者显著更高;远处转移SUVmax中位数两者均为5.0(z=-0.381,P=0.703),无显著差异;原发肿瘤[68Ga]Ga-NYM046摄取越高对应碳酸酐酶IX表达越高,R²值为0.8274。

临床怎么用

  • 原文结论认为[68Ga]Ga-NYM046 PET/CT为检测透明细胞肾细胞癌患者的原发肿瘤、受累淋巴结和远处转移提供了一种可行的策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study aimed to investigate the diagnostic efficacy of [68Ga]Ga-NYM046 PET/CT in animal models and patients with clear cell renal cell carcinoma (ccRCC) and to compare its performance with that of 18F-FDG PET/CT. Methods: The in vivo biodistribution of [68Ga]Ga-NYM046 was evaluated in mice bearing OS-RC-2 xenografts. Twelve patients with ccRCC were included in the study; all completed paired [68Ga]Ga-NYM046 PET/CT and 18F-FDG PET/CT. The diagnostic efficacies of these 2 PET tracers were compared. Moreover, the positive rate of carbonic anhydrase IX in the pathologic tissue sections was compared with the SUVmax obtained by PET/CT. Results: The tumor accumulation of [68Ga]Ga-NYM046 at 1 h after injection in OS-RC-2 xenograft tumor models was 7.21 ± 2.39 injected dose per gram of tissue. Apart from tumors, the kidney and stomach showed high-uptake distributions. In total, 9 primary tumors, 96 involved lymph nodes, and 147 distant metastases in 12 patients were evaluated using [68Ga]Ga-NYM046 and 18F-FDG PET/CT. Compared with 18F-FDG PET/CT, [68Ga]Ga-NYM046 PET/CT detected more primary tumors (9 vs. 1), involved lymph nodes (95 vs. 92), and distant metastases (137 vs. 127). In quantitative analysis, the primary tumors' SUVmax (median, 13.5 vs. 2.4; z = -2.668, P = 0.008) was significantly higher in [68Ga]Ga-NYM046 PET/CT. Conversely, the involved lymph nodes' SUVmax (median, 5.9 vs. 7.6; z = -3.236, P = 0.001) was higher in 18F-FDG PET/CT. No significant differences were found for distant metastases (median SUVmax, 5.0 vs. 5.0; z = -0.381, P = 0.703). Higher [68Ga]Ga-NYM046 uptake in primary tumors corresponded to higher expression of carbonic anhydrase IX, with an R 2 value of 0.8274. Conclusion: [68Ga]Ga-NYM046 PET/CT offers a viable strategy for detecting primary tumors, involved lymph nodes, and distant metastases in patients with ccRCC.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Lou K, Wang J, He H, et al. Value of [68Ga]Ga-NYM046 PET/CT, in Comparison with 18F-FDG PET/CT, for Diagnosis of Clear Cell Renal Cell Carcinoma. J Nucl Med. 2024. PMID: 39542699. doi:10.2967/jnumed.124.267527

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。